For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged atrial fibrillation, atrial fibrillation patient populations, Boehringer Ingelheim, dabigatran etexilate, ESC Congress 2013, ESC Congress 2013 in Amsterdam, European Society of Cardiology, Ingelheim, novel oral anticoagulant (NOAC) Pradaxa®, optimal stroke protection, pivotal RE-LY® trial, Pradaxa®, prevention of stroke and systemic embolism, Professor Klaus Dugi, Sara McClelland
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?